Update, November 3, 2026: After the district court sent the analogous-product question back to the FDA, the agency again concluded in an October 2 decision that retatrutide is not a biological product and said an application would need to use the drug pathway. This is an FDA decision on remand, not a new appellate ruling or an approval. Lilly appealed the district-court judgment, and the Seventh Circuit heard argument on September 24, 2026.
Why do sources describe retatrutide as having 39, 40 or 41 amino acids? The counts depend on which components are included and the regulatory definition applied. FDA’s protein definition concerns a specific alpha-amino-acid polymer exceeding 40 amino acids; the classification dispute is separate from whether retatrutide is approved.
How many amino acids does retatrutide contain?
That sounds like a question with one correct answer.
Instead, it helped trigger a federal lawsuit between Eli Lilly and the FDA.
For the legal timeline, see why Lilly challenged the FDA’s classification. A separate overview considers what could happen if FDA approval is granted. For the scientific background, see our retatrutide triple-agonist research overview.
Depending on which components are counted, how they are connected, and which regulatory definition is applied, the answer has been described as 39, 40, or 41.
The disagreement matters because FDA defines a protein as an alpha-amino-acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.
That means the difference between 40 and 41 is not academic.
It can be the difference between being treated as a peptide drug and potentially qualifying as a protein under the biological-product framework.
FDA’s greater-than-40 rule
FDA’s regulation does not say that every molecule containing something people casually call 41 amino acids is automatically a protein.
The agency’s definition is more specific.
The molecule must be:
- An alpha-amino-acid polymer
- With a specific, defined sequence
- Greater than 40 amino acids in size
Each part matters.
Not every amino-acid-like component necessarily counts as an alpha amino acid.
Not every connected chemical group necessarily belongs to one qualifying polymer.
This is where retatrutide becomes regulatory catnip for attorneys.
Why different counts exist
The 2025 district-court order, clarified in an amended order on October 3, 2025, describes FDA’s position at that stage as follows:
How to interpret conflicting counts: A sequence graphic, a supplier’s nominal residue count and the FDA’s legal definition do not necessarily apply identical counting conventions. The chemical questions include what constitutes the relevant polymer and how nonstandard components are treated. The regulatory question also includes the agency’s analogous-to-a-protein analysis. For the court and agency sequence, read our Lilly and FDA classification timeline. A headline number alone cannot settle either question.
Retatrutide contains, at most, 40 alpha amino acids and one non-alpha amino acid. Because the protein definition requires more than 40 alpha amino acids, FDA concluded that the molecule does not qualify.
Some explanations instead describe retatrutide as having a principal sequence of 39 alpha amino acids plus additional associated residues or structural components.
This is why readers encounter several counts:
- 39, referring to the principal alpha-amino-acid backbone in some descriptions
- 40, reflecting FDA’s maximum count of qualifying alpha amino acids
- 41, reflecting Lilly’s broader treatment of the complete structure or total residues
Those numbers are not necessarily competing descriptions of an ordinary straight chain.
They reflect different ways of interpreting the molecule for a specific legal definition.
Why did Lilly disagree?
Lilly argued that FDA’s interpretation was too narrow and inconsistent with the governing regulation or statute.
From Lilly’s perspective, the complete molecule crossed the relevant size threshold and should be treated as a protein or biological product.
FDA took the opposite position.
The agency focused on alpha amino acids forming the qualifying polymer and excluded the non-alpha component from the count.
The district court ultimately upheld FDA’s interpretation on the protein question. It found that FDA had a permissible basis for focusing on qualifying alpha amino acids under the regulation.
In that part of the case, FDA prevailed.
Then came “analogous to a protein”
Lilly had another argument.
Federal law covers not only specified biological substances such as proteins, but also certain analogous products.
Lilly argued that even if retatrutide fell just outside FDA’s protein definition, the complete molecule could still be considered analogous to a protein.
FDA rejected that position because retatrutide lacked what it viewed as a fundamental defining property of a protein: more than 40 alpha amino acids.
The court found FDA’s reasoning defective.
If a product could never be analogous to a protein unless it already met the defining protein threshold, the analogous category risked becoming circular.
The court therefore vacated FDA’s analogous-product determination and required the agency to reconsider it. On October 2, 2026, the FDA issued the subsequent decision described in the update above; the district-court remand itself did not order a biologic designation.
Did Lilly add an extra amino acid to block competitors?
There is no publicly established evidence proving that Lilly deliberately designed retatrutide’s structure solely to secure biological-product status or prevent compounding.
That theory may sound plausible to people familiar with pharmaceutical strategy.
Plausibility is not proof.
What the public record does establish is that Lilly:
- Asked FDA to treat retatrutide as a biological product
- Challenged FDA’s counting and classification
- Sued after FDA refused
- Won partial relief on the analogous-product issue
- Announced plans to submit a BLA
Those actions show that classification matters greatly to Lilly.
They do not establish the precise intent behind every molecular-design decision.
Why can two residues be worth so much?
If retatrutide qualifies as a reference biological product, it could receive a different exclusivity framework and face follow-on competition through the biosimilar pathway rather than the generic pathway.
That can influence:
- The timing of direct copy competition
- Development costs for competitors
- Analytical and manufacturing requirements
- Commercial pricing power
- Investment value
- Long-term market control
For a modest product, that distinction would still matter.
For a potential global obesity blockbuster, it could be worth billions.
Is the scientific question settled?
The molecule’s chemical composition can be described objectively.
The regulatory classification remains a legal and administrative question because the dispute concerns how the statutory and regulatory language applies to that structure.
The district court upheld FDA’s interpretation of “protein” but required reconsideration of the analogous-product pathway.
Lilly previously announced a Q1 2027 biologics filing plan. After the remand, the FDA’s October 2 decision stated that an application would follow the drug pathway. The classification dispute remains separate from any approval decision.
That means the fight is no longer merely theoretical.
The bottom line
The retatrutide amino-acid controversy is not simply about whether someone miscounted a chain.
It is about:
- Which components qualify
- Which components belong to the relevant polymer
- Whether only alpha amino acids count
- Whether a molecule falling outside the protein definition can still be analogous to a protein
- Which regulatory framework will govern the product
FDA says retatrutide does not satisfy its technical protein definition.
Lilly argues the molecule belongs within the biological-product framework anyway.
The district court required FDA to reconsider the second issue. FDA subsequently reaffirmed its drug-pathway determination on remand; that agency decision is distinct from the appellate proceedings.
So the next time someone says the lawsuit is “just about one amino acid,” remember:
That one amino acid may sit between two different regulatory worlds.